New drug combo aims to shrink pancreatic tumors before surgery
NCT ID NCT05908747
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests whether adding the drug surufatinib to standard chemotherapy can help shrink pancreatic tumors enough to allow successful surgery. It involves 29 adults with locally advanced or borderline resectable pancreatic cancer. The main goal is to see how many tumors can be completely removed with clear margins.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?
- Can a pill rouse the immune system against pancreatic cancer?